TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc.Oct 13 2010

TrovaGene, Inc. (Pink Sheets:TROV), a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

“Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine.”

"We believe that this patent is a valuable addition to our extremely broad IP estate," commented Dr. David Robbins, TrovaGene's Vice President of Research and Development. "It provides a basis for diagnosing and monitoring bacterial or parasitic infections using a sample that is stable, easy to collect, and truly non-invasive.

Patent 7,803,929 complements the previously issued U.S. patents including the reissued patent RE39,920 which covers detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples.